Shares of Depomed Inc. (DEPO, $5.61, -$0.97, -14.74%) slid after the pharmaceutical company disclosed that Abbott Laboratories (ABT, $47.48, +$0.28, +0.59%) said it isn't obligated to launch and commercialize Depomed's oral treatment for post-herpetic neuralgia. The specialty pharmaceutical company on Tuesday said it plans to engage in mediation with Abbott regarding Abbott's commercialization obligations. The product candidate, known as DM-1796, has completed Phase 3 clinical development and has been licensed to Abbott in the U.S., Canada and Mexico.
Market Data 
Markets 
AI
